StockData
Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc. (FLGT) stock

FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$24.21+0.14 (+0.56%)

Close on Nov 17, 2026Market cap $666.15MP/E –Yield –

Fulgent Genetics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Fulgent Genetics's ebitda for the twelve months ending Jun 30, 2026 was -$96.46M. For fiscal 2025 it was -$66.97M. The highest annual figure on record is $686.96M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$66.97M–
FY2024Dec 31, 2024-$48.99M–
FY2023Dec 31, 2023-$169.39M-180.2%
FY2022Dec 31, 2022$211.19M-69.3%
FY2021Dec 31, 2021$686.96M+134.4%
FY2020Dec 31, 2020$293.12M+17358.0%
FY2019Dec 31, 2019$1.68M–
FY2017Dec 31, 2017-$1.75M-184.0%
FY2016Dec 31, 2016$2.09M–
FY2015Dec 31, 2015-$4.44M–
FY2014Dec 31, 2014-$794.00K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$28.40M–
Q1 FY2026Mar 31, 2026-$28.62M–
Q4 FY2025Dec 31, 2025-$30.13M–
Q3 FY2025Sep 30, 2025-$9.31M–
Q2 FY2025Jun 30, 2025-$13.66M–
Q1 FY2025Mar 31, 2025-$13.88M–
Q4 FY2024Dec 31, 2024-$9.94M–
Q3 FY2024Sep 30, 2024-$11.16M-268.2%
Q2 FY2024Jun 30, 2024-$12.75M–
Q1 FY2024Mar 31, 2024-$15.14M–
Q4 FY2023Dec 31, 2023-$144.59M–
Q3 FY2023Sep 30, 2023$6.63M-34.8%
Q2 FY2023Jun 30, 2023-$13.49M-163.8%
Q1 FY2023Mar 31, 2023-$17.95M-108.7%
Q4 FY2022Dec 31, 2022-$26.75M-117.3%
Q3 FY2022Sep 30, 2022$10.17M-93.7%
Q2 FY2022Jun 30, 2022$21.14M-79.1%
Q1 FY2022Mar 31, 2022$206.63M-23.1%
Q4 FY2021Dec 31, 2021$154.35M-32.0%
Q3 FY2021Sep 30, 2021$162.45M+152.9%
Q2 FY2021Jun 30, 2021$101.32M–
Q1 FY2021Mar 31, 2021$268.84M–
Q4 FY2020Dec 31, 2020$227.03M–
Q3 FY2020Sep 30, 2020$64.25M+25094.1%
Q1 FY2018Mar 31, 2018-$1.68M-365.9%
Q4 FY2017Dec 31, 2017-$1.60M-195.1%
Q3 FY2017Sep 30, 2017-$1.04M–
Q2 FY2017Jun 30, 2017$255.00K–
Q1 FY2017Mar 31, 2017$631.00K–
Q4 FY2016Dec 31, 2016$1.68M–
Q3 FY2016Sep 30, 2016-$391.00K–

More Fulgent Genetics figures

See a number that looks wrong?